Usage of perindopril after myocardial infarction – patient with cardiovascular diseases in medical history. Experience of one of Warsaw clinical centres Case report
Article Sidebar
Main Article Content
Abstract
Cardiovascular diseases are more than common. If the patient is not admitted do the hospital due to cardiovascular disease, there are some cardiovascular diseases in his or her medical history at least. That is why cardiovascular drugs should always be taken into consideration. Cardiovascular risk after myocardial infarction is always very high even if the main reason for admitting to the hospital will by COPD exacerbation, uncontrolled diabetes or infection. We present two clinical cases in which cardiovascular diseases seems to by “only” background. In the same time this background make us to reconsider the hole pharmacotherapy of our patients.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Montalescot G., Sechtem U., Achenbach S. et al.; Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw postępowania w stabilnej chorobie wieńcowej: Wytyczne ESC dotyczące postępowania w stabilnej chorobie wieńcowej w 2013 roku. Kardiol. Pol. 2013; 71(supl. X): 243-318.
3. Tykarski A., Narkiewicz K., Gaciong Z. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśn. Tętn. 2015; 15: 55-82.
4. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362(9386): 782-788.
5. Warwick J., Falaschetti E., Rockwood K. et al.: No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015; 13: 78. http://doi.org/10.1186/s12916-015-0328-1.
6. Dahlöf B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
7. PROGRESS Collaborative Group: Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033-1041. Erratum in: Lancet 2001; 358(9292): 1556, Lancet 2002; 359(9323): 2120.
8. Waeber B., de la Sierra A., Ruilope L.M.: The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am. J. Cardiovasc. Drugs 2009; 9(5): 283-291. http://doi.org/10.2165/10061600-000000000-00000.
9. Zoungas S.: Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. N. Engl. J. Med. 2014; 371: 1392-1406. http://doi.org/10.1056/NEJMoa1407963.